RxDoctor Payments DataLook up a doctor →

Guinevere Que

Nurse Practitioner · Washington, DCNPI 1821158783

Payments from drug & device makers

$27,125in general payments, 2019–2025

Across 873 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$15K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Impel Pharmaceuticals Inc.$1K
  • Pfizer$821
  • Lilly USA, LLC$732
  • Lundbeck LLC$707
  • plus $6K from 46 others

What the payments were for

  • Speaking & faculty fees$11,38442%
  • Food & beverage$15,56957%
  • Education$1721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,125 in reported general payments places this provider in the 95th percentile of 224 nurse practitioner providers in District of Columbia.

See all nurse practitioner providers in District of Columbia

Medicare billing

Part B allowed, 2024
$51,828
Medicare patients
117
Services billed
2,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ajovy AutoinjectorFremanezumab-Vfrm33$32,419
Emgality PenGalcanezumab-Gnlm15$22,201
Sumatriptan Succinate40$5,049
Memantine Hcl ErMemantine Hcl17$2,509
Gabapentin75$1,421
Duloxetine Hcl27$784
Zolpidem Tartrate ErZolpidem Tartrate16$773
Naratriptan Hcl13$756
Donepezil Hcl48$719
Memantine Hcl28$690
Trazodone Hcl45$652
Bupropion XlBupropion Hcl15$442
RizatriptanRizatriptan Benzoate22$442
Venlafaxine Hcl ErVenlafaxine Hcl24$419
Divalproex Sodium11$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Upsher-smith Laboratories LLCTopiramate$128$25819 claims
Almatica Pharma LLCSertraline Hcl$18$21723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 224 nurse practitioner providers in District of Columbia.

Other nurse practitioner in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →